IMV’s DPX Delivery Technology to be Featured in Two Electronic Posters at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference


Content of the article

DARTMOUTH, Nova Scotia and CAMBRIDGE, Mass. – IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a new class of immunotherapies for difficult-to-treat cancers, today announced that two abstracts featuring two DPX were accepted for virtual poster presentation at the upcoming AACR-NCI-EORTC International Virtual Conference on Molecular Targets and Cancer Therapy October 7-10, 2021.

Poster # 1:

Content of the article

Survivin peptides formulated in the DPX delivery platform, rather than standard emulsions, elicit a robust and sustained T cell response to survivin in patients with advanced and recurrent ovarian cancer.

Yogesh Bramhecha, Ph.D.,
Director of Translational Research, IMV Inc.


Poster # 2:

DPX-SurMAGE, a novel dual-target immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in a preclinical model.

Yves Fradet, MD

Professor, Department of Surgery

Faculty of Medicine, Laval University, Quebec


Full abstracts and electronic posters will be available on request on the conference platform on October 7, 2021 at 9 a.m. ET. Both electronic posters will be available in the Scientific Publications and Posters section of the IMV website.

About IMV

IMV Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more widely applicable, and more widely accessible to people with difficult-to-treat cancer and other unmet medical needs. IMV is the pioneer of a new class of cancer immunotherapies based on the company’s proprietary delivery platform (DPX). This patented technology exploits a differentiated mechanism of action that generates targeted and sustained immune activation with limited side effects. IMV’s lead candidate, maveropepimut-S (formerly called DPX-Survivac), is a T-cell-activating immunotherapy that combines the utility of the platform with a new cancer target: survivin. IMV is currently evaluating maveropepimut-S in advanced breast and ovarian cancer, as well as a combination therapy in several clinical studies with Merck. IMV is also developing another DPX-based immunotherapy: DPX-SurMAGE, a dual-target immunotherapy that will be evaluated in subjects with bladder cancer later this year. For more information, visit and connect with us on Twitter and LinkedIn.

IMV forward-looking statements

This press release contains forward-looking information under applicable securities laws. All information that deals with activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use words such as “will”, “may”, “possible”, “believe”, “expect”, “continue”, “anticipate” and other similar terms. Forward-looking statements are based on the estimates and opinions of management as of the date the statements are made. In the press release, these forward-looking statements include, but are not limited to, statements regarding the ability of the Company to advance its development strategy, as well as the outlook for its primary field of immunotherapy and its other pipeline of immunotherapy candidates. However, they should not be taken as a representation that any of the plans will be realized. Actual results may differ materially from those presented in this press release due to risks affecting the Company, including access to capital, successful design and completion of clinical trials and timely receipt of all approvals. regulations to begin, and then continue, clinical studies. and testing and receiving all regulatory approvals to market its products. IMV Inc. assumes no responsibility for updating any forward-looking statements in this press release, except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and these risks and uncertainties include, without limitation, the ability to access capital, the success and, generally, the on-time completion of the business. clinical trials and studies and the receipt of all regulatory approvals as well as other risks detailed from time to time in our current quarterly filings and our annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current annual information form, as well as its annual audited consolidated financial statements which are available on SEDAR at at and on EDGAR at

Content of the article

See the source version on



Investor Relations

Joy Bessenger, Senior Vice President, Investor Relations and Corporate Strategy
O: (902) 492.1819
E: [email protected]

Marc Jasmin, Senior Director, Investor Relations, IMV Inc.
O: (902) 492-1819 ext: 1042
M: (514) 617-9481 E: [email protected]

Irina Koffler, Managing Director, LifeSci Advisors
O: (646) 970-4681
M: (917) 734-7387
E: [email protected]


Delphine Davan, Senior Director, Communications, IMV inc.
M: (514) 968 1046
E: [email protected]

Madeline Joanis, Senior Account Manager, LifeSci Communications
M: (603) 479 5267
E: [email protected]


Leave A Reply

Your email address will not be published.